A Pilot Study of Additional Chinese Formula for Concurrent Chemoradiotherapy in Oral Cavity Cancer Patients

China Medical University

Status and phase: Completed; Phase 1

Conditions: Chemoradiotherapy; Head and Neck Neoplasm

Treatments: Drug: SZKJT(San-Zhong-Kui-Jian-Tang)

Study type: Interventional

Funder types: Other

Identifiers

NCT05590650

CMUH106-REC3-149

Details and patient eligibility

About

The goal of this clinical trial is to learn about the clinical efficacy of San-Zhong-Kui-Jian-Tang (SZKJT), a formula of Chinese medicine in head and neck cancer patients receiving concurrent chemoradiotherapy (CCRT) treatments. The main questions it aims to answer are:

• Can SZKJT improve the completion rate of CCRT?
• Can SZKJT reduce the adverse effects of CCRT?
• How SZKJT affect the quality of life in the patients receiving CCRT
• How about the safety of using SZKJT in the patients receiving CCRT

Participants will be asked to:

• take SZKJT for 9 weeks during the whole CCRT course
• take questionnaires of quality of life

Full description

San-Zhong-Kui-Jian-Tang (SZKJT) is originated from the Secret Treasure of the Orchid Chamber written by Gao Li (AC1180 - 1251). SZKJT contains 16 herbs to treat abnormal swelling or nodules. In the theory of Chinese medicine, SZKJT can clear heat and resolve toxin, which leads to disperse swelling and binds in nodules.

The purpose of this study is to explore the clinical efficacy and safety of SZKJT in improving the completion rate of concurrent chemoradiotherapy (CCRT) in patients with head and neck cancer, and to evaluate the prevention and treatment effects of SZKJT on the side effects of chemoradiotherapy, as well as the improvement of quality of life.

The primary endpoint of the study is the completion rate of CCRT under SZKJT treatment. The secondary endpoints are adverse effects of CTCAE, body constitution questionnaire (BCQ) and the EORTC core quality of life questionnaire (QLQ-C30). Liver and kidney functions are considered as well for adverse effects of SZKJT. We hypothesized that additional SZKJT with CCRT might improve completion rate of CCRT and reduce severity of adverse effects of CCRT.

Enrollment: 21 patients

Sex: All

Ages: 20 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• aged from 20- to 65-year-old;
• firstly diagnosed as head and neck cancer with stage II, III or IV;
• adjuvant therapy with chemotherapy of Cisplatin or combined with radiotherapy after surgery;
• or chemotherapy of Cisplatin for those without surgery;
• wiliness to sign inform consent.

Exclusion criteria

• pregnancy;
• non-Squamous-cell carcinoma;
• secondary cancer or Carcinoma in situ in 5 years;
• any evidence of metastasis;
• abnormality of liver, kidney or bone marrow functions before treatments;
• unstable vital signs;
• episode of acute infection;
• unclear consciousness for inform consent;
• receiving other herbal, complementary or acupuncture therapy.

Trial design

Primary purpose: Supportive Care

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

21 participants in 1 patient group

SZKJT group

Experimental group

Description:

Patients who meet the inclusion criteria and agree to receive concomitant treatment with SZKJT.

Treatment:

Drug: SZKJT(San-Zhong-Kui-Jian-Tang)